Madopar DR® (Dual Release)
Partner: Roche
Madopar DR® is licensed for sale in Switzerland and indicated for the oral treatment of all forms of the Parkinson disease, with the exception of drug induced parkinsonism. Madopar DR® is also indicated to treat idiopathic and symptomatic restless legs syndrome.
SkyePharma manufactures Madopar DR®, using its proprietary Geomatrix™ oral delivery technology, at its facilities in Switzerland for Roche.
For further information on Madopar DR®, see Roche's web site.
Copyright 2008, SkyePharma. All Rights Reserved.
SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom
